Cargando…
Identification and Determination of Impurities in a New Therapeutic Agent for Fatty Liver Disease
Methyl 7,7′-dimethoxy-5′-(morpholinomethyl)-[4,4′-bibenzo[d][1,3] dioxole]-5-carboxylate methanesulfonate (IMM) is an innovative drug for the treatment of nonalcoholic fatty liver disease (NAFLD) owing to its high efficacy and low toxicity. In this study, five minor impurities (I, II, III, IV, and V...
Autores principales: | Shao, Huihui, Feng, Jing, Zhang, Hanyilan, Zhang, Yuanyuan, Qin, Tong, Hu, Yuhua, Zhang, Wenxuan, Wang, Tiesong, Wu, Song, Yang, Qingyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421711/ https://www.ncbi.nlm.nih.gov/pubmed/37575214 http://dx.doi.org/10.1155/2023/3116223 |
Ejemplares similares
-
Determination of Methyl Methanesulfonate and Ethyl Methylsulfonate in New Drug for the Treatment of Fatty Liver Using Derivatization Followed by High-Performance Liquid Chromatography with Ultraviolet Detection
por: Wang, Yue, et al.
Publicado: (2022) -
Development and In Vitro–In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease
por: Zhang, Chi, et al.
Publicado: (2023) -
Identification, synthesis and characterization of avanafil process impurities and determination by UPLC
por: Zhao, Mengmeng, et al.
Publicado: (2022) -
A Rapid Assessment Model for Liver Toxicity of Macrolides and an Integrative Evaluation for Azithromycin Impurities
por: Zhang, Miao-Qing, et al.
Publicado: (2022) -
Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection
por: Zhao, Xintong, et al.
Publicado: (2023)